Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications is a funding call from European Commission – Horizon Europe that closes 17 February 2027 (forthcoming — not yet open). Funding: EUR 8,000,000–10,000,000 per project. Eligibility: Collaborative Horizon Europe project: legal entities in EU Member States or associated countries, normally as a consortium (standard Horizon Europe eligibility, Annex B). Status: forthcoming — submission not yet open.
- Funder
- European Commission – Horizon Europe
- Deadline
- 17 Feb 2027 (125 days)
- Status
- Forthcoming
- Amount
- EUR 8,000,000–10,000,000 per project
- Region / eligibility
- EU Member States & Horizon Europe associated countries
- Career stage
- established / PI
- Fields
- pharma process
- Reference
- HORIZON-HLTH-2027-01-CARE-02
- Official call
- EU Funding & Tenders listing
Eligibility in plain language
Collaborative Horizon Europe project: legal entities in EU Member States or associated countries, normally as a consortium (standard Horizon Europe eligibility, Annex B). Status: forthcoming — submission not yet open.
Who should apply
Medicinal chemists and pharma process / drug-development teams — best fit for PIs and research groups able to join or build a multi-country consortium.
Summary from source
Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Ensuring equal access to innovative, sustainable, and high-quality healthcare”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: Patients benefit from decreased incidence of Adverse Drug Reactions (ADRs) caused by the administration of multiple medications (three or more medicinal products [1] ) and enhanced health outcomes by ensuring safer and more effective use of medication. Healthcare professionals can adopt adverse drug reactions prevention and reduction strategies to integrate genetic and other biomarker information into clinical decision-making to optimise the use of medication, especially in situations of comorbidities. He…